These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 32472221)

  • 1. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
    Schmid SC; Koll FJ; Beckert F; Seitz AK
    Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
    Todenhöfer T; Boegemann M
    Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Teo MY; Rosenberg JE
    Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of immunotherapy in bladder cancer.
    Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
    Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The landscape of immunotherapy in metastatic urothelial carcinoma.
    Teo MY; Iyer G
    Curr Opin Urol; 2019 Nov; 29(6):643-648. PubMed ID: 31567441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
    Einstein DJ; Sonpavde G
    Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.
    Kim IH; Lee HJ
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT).
    Schmid SC; Koll FJ; Rödel C; Maisch P; Sauter A; Beckert F; Seitz A; Kübler H; Flentje M; Chun F; Combs SE; Schiller K; Gschwend JE; Retz M
    BMC Cancer; 2020 Jan; 20(1):8. PubMed ID: 31900121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Achkar T; Parikh RA
    Urol Clin North Am; 2018 May; 45(2):257-266. PubMed ID: 29650141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in the treatment of advanced bladder cancer.
    Godwin JL; Hoffman-Censits J; Plimack E
    Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
    Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
    Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative systemic therapy for bladder cancer.
    Eulitt PJ; Bjurlin MA; Milowsky MI
    Curr Opin Urol; 2019 May; 29(3):220-226. PubMed ID: 30855376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.